WuXi AppTec: Subsidiary equity transferred to a newly established wholly-owned subsidiary
2025-09-02 17:23:42

WuXi AppTec announced plans to transfer its 98.9% stake in Shanghai Hequan Pharmaceuticals, held by Shanghai WuXi, to WuXi AppTec (Shanghai) Pharmaceutical Research & Development Co., Ltd. Upon completion of this equity transfer, WuXi Research & Development will directly hold 98.9% of the target company's shares. This equity transfer will not affect the scope of the company's consolidated financial statements, the substantive operations of the target company, or its profits or overall equity.
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
ASIA TECH WIRE

Grasp technology trends

Download